Checkpoint Therapeutics (NASDAQ:CKPT) Research Coverage Started at D. Boral Capital

D. Boral Capital began coverage on shares of Checkpoint Therapeutics (NASDAQ:CKPT) in a research note issued to investors on Monday, Marketbeat.com reports. The brokerage issued a buy rating and a $9.00 price objective on the stock.

A number of other brokerages have also commented on CKPT. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Checkpoint Therapeutics in a research report on Monday, December 16th. Lake Street Capital boosted their price objective on Checkpoint Therapeutics from $4.00 to $7.00 and gave the company a “buy” rating in a report on Monday, December 16th.

Checkpoint Therapeutics Stock Performance

Checkpoint Therapeutics stock opened at $3.33 on Monday. The stock has a market capitalization of $162.61 million, a price-to-earnings ratio of -1.81 and a beta of 1.36. Checkpoint Therapeutics has a 52-week low of $1.38 and a 52-week high of $4.50. The stock’s 50 day moving average price is $3.63 and its two-hundred day moving average price is $2.89.

Checkpoint Therapeutics (NASDAQ:CKPT) last issued its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.08). On average, equities research analysts forecast that Checkpoint Therapeutics will post -0.91 EPS for the current year.

Insider Transactions at Checkpoint Therapeutics

In related news, CFO William Garrett Gray sold 268,432 shares of Checkpoint Therapeutics stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $4.01, for a total transaction of $1,076,412.32. Following the transaction, the chief financial officer now owns 1,032,754 shares of the company’s stock, valued at $4,141,343.54. The trade was a 20.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO James F. Oliviero III sold 220,230 shares of the stock in a transaction on Thursday, December 19th. The shares were sold at an average price of $3.38, for a total value of $744,377.40. Following the completion of the sale, the chief executive officer now directly owns 3,194,583 shares of the company’s stock, valued at $10,797,690.54. The trade was a 6.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. B. Riley Wealth Advisors Inc. increased its stake in Checkpoint Therapeutics by 366.3% in the 2nd quarter. B. Riley Wealth Advisors Inc. now owns 229,200 shares of the company’s stock valued at $493,000 after buying an additional 180,050 shares during the last quarter. PVG Asset Management Corp bought a new position in shares of Checkpoint Therapeutics in the second quarter valued at approximately $295,000. Geode Capital Management LLC increased its position in shares of Checkpoint Therapeutics by 41.2% during the third quarter. Geode Capital Management LLC now owns 427,651 shares of the company’s stock valued at $958,000 after acquiring an additional 124,787 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its holdings in Checkpoint Therapeutics by 160.0% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 130,000 shares of the company’s stock worth $291,000 after acquiring an additional 80,000 shares during the period. Finally, HB Wealth Management LLC boosted its position in Checkpoint Therapeutics by 96.9% in the fourth quarter. HB Wealth Management LLC now owns 153,560 shares of the company’s stock worth $513,000 after purchasing an additional 75,560 shares during the last quarter. 22.00% of the stock is owned by institutional investors.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.